CDC Panel (Barely) Prefers Shingrix Shingles Vaccine Over Zostavax

In 8-7 vote, Advisory Committee on Immunization Practices recommends GSK's Shingrix as preferred shingles vaccine given its higher efficacy compared to Merck's Zostavax.

Red and blue arrow elevators with businessmen going up and down.

GlaxoSmithKline PLC now has a chance to take over the US shingles vaccine market after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) voted 8-7 to recommend Shingrix over Merck & Co. Inc.'s Zostavax.

The panel considered the appropriate use of Shingrix at its Oct. 25 meeting. Those who voted against recommending a preference...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers